ClinicalTrials.gg
CompletedNCT05708612Updated Oct 30, 2026

Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

An interventional study of Medical Device (SimplyFI) in Fecal Incontinence, sponsored by A.M.I. Agency for Medical Innovations GmbH. Completed at 5 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by A.M.I. Agency for Medical Innovations GmbH · Not applicable, Interventional, and Treatment

How we know

Updated Oct 30, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of the clinical investigation is to verify that the device under investigation (SimplyFI) is appropriate to significantly improve fecal incontinence in patients in whom its use is indicated.

02

Conditions studied

  • Fecal Incontinence

Browse trials for

Keywords

  • Surgical Treatment
  • Implant
03

In context

Fecal Incontinence

285 studies on the registry are indexed under Fecal Incontinence; 52 are open to participants now.

This study's enrollment of 43 is below the median of 50 across 204 interventional studies indexed under Fecal Incontinence.

Browse Fecal Incontinence studies →

Lead sponsor

A.M.I. Agency for Medical Innovations GmbH is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both male and female subjects
  • Age ≥ 18 years, \<85 years
  • Subject has failed standard conservative therapy for fecal incontinence (at least 6 months)
  • Subject is a surgical candidate
  • Subject is willing and able to cooperate with follow-up examinations
  • Subject has been informed of the study procedures and the treatment and has signed an form and provided authorization to use and disclose information for research purposes.

Exclusion criteria

Exclusion Criteria:

  • Treatment with another drug or investigational device
  • Unable to understand study requirements or is unable to comply with follow-up schedule
  • according to the instruction for use of the device
  • Pregnancy or nursing, or plans to become pregnant
  • History of significant obstructed defecation or other significant chronic defecatory motility disorders
  • Current, external full thickness rectal prolapse or vaginal prolapse
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Systemic disease as source of FI (scleroderma, neurologic disorders, Crohn's)
  • Active pelvic infection
  • Chronic diarrhea
  • Medical history of anal, rectal, or colon cancer
  • Prior anterior resection of the rectum
  • Medical history of pelvic radiation therapy
  • Significant scarring of the recto-vaginal septum, a permanent implant in the rectovaginal septum, or a history of recto-vaginal fistula
  • Previous anorectal posterior compartment surgery
  • History of complex anal fistula
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Implantation of SimplyFI

    Long-term non-active implant

    Procedure: Medical Device (SimplyFI)

Interventions

  • ProcedureMedical Device (SimplyFI)

    Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.

06

What researchers measure

Primary outcomes

  1. Safety-related complications and adverse events

    The primary endpoint is safety-related complications and adverse events during follow-up until 12 months after surgery.

    Time frame: 12 months

Secondary outcomes

  1. Cure of fecal incontinence (Fecal Incontinence Quality of Life Scale (FIQLs))

    The secondary endpoint is to evaluate the change of fecal incontinence assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. Fecal Incontinence Quality of Life scale (all subscale scores 1-4). Scales range from 1 to 5, with a 1 indicating a lower functional status of quality of life. Scale scores are the average (mean) response to all items in the scale.

    Time frame: 12 months

  2. Quality of Life (St. Mark's incontinence score (SMIS))

    The secondary endpoint is to evaluate the change of Quality of Life assessed by validated scores (changes from baseline to 1 week, 1 months, 3 months, 6 months) until 12 months after surgery. St. Marks incontinence score contains 7 questions, and a higher total score means a worse outcome

    Time frame: 12 months

07

Study locations

5 sites
  • Göttlicher Heiland Krankenhaus
    Vienna, Austria
  • Medical University Vienna
    Vienna, Austria
  • Klinikum Bielefeld Rosenhöhe
    Bielefeld, Germany
  • Hospital Ruber Internacional
    Madrid, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
08

References and documents

Publications

  • Dawoud C, Devesa JM, Lohnert M, Vicente R, Metwalli SA, Riss S. Artificial sphincter with a new silicone band for treating faecal incontinence: IDEAL 2b prospective multicentre trial. BJS Open. 2025 Sep 8;9(5):zraf112. doi: 10.1093/bjsopen/zraf112. PubMed 41123163 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Mar 2026, 35 months.

Of 86 interventional studies with no phase under Fecal Incontinence, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's 35 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Apr 2026 → Mar 2026 and completion Sep 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 1, 2023
StartActual
Apr 1, 2023
Primary completionActual
Mar 28, 2026was Apr 2026
CompletionActual
Oct 28, 2026was Sep 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 30, 2026
Primary completion
Apr 2026→Mar 28, 2026 (actual)
Oct 30, 2026
Study completion
Sep 2026→Oct 28, 2026 (actual)
Oct 30, 2026
Enrollment
36 (estimated)→43 (actual)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Active, not recruiting→Completed
    Primary completion Apr 2026→Mar 28, 2026 (now actual)
    Study completion Sep 2026→Oct 28, 2026 (now actual)
    Enrollment 36 (estimated)→43 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05708612
Lead sponsor
A.M.I. Agency for Medical Innovations GmbH
Responsible party
Sponsor
First posted
Feb 1, 2023
Start date
Apr 1, 2023
Primary completion
Mar 28, 2026
Completion
Oct 28, 2026
Last update
Oct 30, 2026

Study contacts

Stefan Riss, Prof. PD Dr.
principal investigator · Medical University of Vienna
José Manuel Devesa Múgica, Dr.
principal investigator · Hospital Ruber Internacional

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion